Expand / Collapse search
Watch TV
☰

Quotes displayed in real-time or delayed by at least 15 minutes. Market data provided by Factset. Powered and implemented by FactSet Digital Solutions.  Legal Statement.

This material may not be published, broadcast, rewritten, or redistributed. ©2026 FOX News Network, LLC. All rights reserved. FAQ - New Privacy Policy

establishment labs holdings inc - ESTA

ESTA

Close Chg Chg %
72.92 -4.58 -6.28%

Closed Market

68.34

-4.58 (6.28%)

Volume: 522.61K

Last Updated:

Jan 9, 2026, 4:00 PM EDT

Trade Now

Company Overview: establishment labs holdings inc - ESTA

ESTA Key Data

Open

$73.38

 Day Range

68.24 - 74.65

52 Week Range

26.56 - 78.24

 Market Cap

$2.03B

Shares Outstanding

29.06M

 Public Float

26.23M

Beta

0.92

 Rev. Per Employee

N/A

P/E Ratio

N/A

 EPS

-$2.85

Yield

0.00%

 Dividend

N/A

EX-DIVIDEND DATE

SHORT INTEREST

N/A

AVERAGE VOLUME

440.24K

  

ESTA Performance

1 Week
 
 -0.73%
 
1 Month
 
 -5.75%
 
3 Months
 
 75.50%
 
1 Year
 
 49.25%
 
5 Years
 
 80.27%
 

ESTA Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 9
Full Ratings ➔

About establishment labs holdings inc - ESTA

Establishment Labs Holdings, Inc. is a technology company, which engages in the design, development, manufacture, and marketing of silicone breast implants. It generates income from customers in Europe, the Middle East, Latin America, and Asia. The firm's products include Motiva Implants, Motiva Flora Tissue Expander, Motiva Ergonomix, and Motiva Ergonomix2. The company was founded by Juan Jose Chacon-Quiros in 2004 and is headquartered in Alajuela, Costa Rica.

ESTA At a Glance

Establishment Labs Holdings, Inc.
Building B15 and 25
Coyol, Alajuela
Phone 506-2434-2400 Revenue 166.03M
Industry Medical Specialties Net Income -84,596,000.00
Sector Health Technology 2024 Sales Growth 0.529%
Fiscal Year-end 12 / 2025 Employees 1,018
View SEC Filings

ESTA Valuation

P/E Current N/A
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) N/A
Price to Sales Ratio 7.815
Price to Book Ratio 24.978
Price to Cash Flow Ratio N/A
Enterprise Value to EBITDA -33.774
Enterprise Value to Sales 8.627
Total Debt to Enterprise Value 0.157

ESTA Efficiency

Revenue/Employee 163,089.391
Income Per Employee -83,100.196
Receivables Turnover 2.554
Total Asset Turnover 0.54

ESTA Liquidity

Current Ratio 3.56
Quick Ratio 2.391
Cash Ratio 1.323

ESTA Profitability

Gross Margin 65.969
Operating Margin -30.108
Pretax Margin -50.973
Net Margin -50.954
Return on Assets -27.49
Return on Equity -236.665
Return on Total Capital -30.388
Return on Invested Capital -34.762

ESTA Capital Structure

Total Debt to Total Equity 424.322
Total Debt to Total Capital 80.928
Total Debt to Total Assets 64.958
Long-Term Debt to Equity 421.471
Long-Term Debt to Total Capital 80.384
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Establishment Labs Holdings Inc - ESTA

Collapse All in section
All values USD millions. 2021 2022 2023 2024 5-year trend
Sales/Revenue
126.68M 161.70M 165.15M 166.03M
Sales Growth
+49.61% +27.64% +2.13% +0.53%
Cost of Goods Sold (COGS) incl D&A
41.28M 55.11M 58.17M 56.50M
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
4.11M 4.17M 4.88M 7.58M
Depreciation
2.91M 2.97M 3.68M 5.48M
Amortization of Intangibles
1.20M 1.20M 1.20M 2.10M
COGS Growth
+28.30% +33.50% +5.57% -2.88%
Gross Income
85.40M 106.60M 106.98M 109.53M
Gross Income Growth
+62.67% +24.81% +0.36% +2.38%
Gross Profit Margin
+67.42% +65.92% +64.78% +65.97%
2021 2022 2023 2024 5-year trend
SG&A Expense
110.54M 146.25M 172.00M 159.51M
Research & Development
18.32M 20.27M 26.43M 19.71M
Other SG&A
92.23M 125.98M 145.57M 139.81M
SGA Growth
+37.46% +32.30% +17.61% -7.26%
Other Operating Expense
- - - -
-
Unusual Expense
- - (737.00K) 18.32M
-
EBIT after Unusual Expense
(24.40M) (57.97M) (65.03M) (49.99M)
Non Operating Income/Expense
(6.25M) (3.09M) 1.84M (13.81M)
Non-Operating Interest Income
23.00K 87.00K 1.02M 1.48M
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
9.06M 11.76M 15.39M 20.83M
Interest Expense Growth
-3.32% +29.77% +30.89% +35.31%
Gross Interest Expense
9.06M 11.76M 15.39M 20.83M
Interest Capitalized
- - - -
-
Pretax Income
(39.71M) (72.82M) (78.58M) (84.63M)
Pretax Income Growth
-4.46% -83.38% -7.91% -7.69%
Pretax Margin
-31.35% -45.04% -47.58% -50.97%
Income Tax
1.43M 2.39M (81.00K) (32.00K)
Income Tax - Current - Domestic
289.00K 114.00K 297.00K 183.00K
Income Tax - Current - Foreign
1.13M 2.19M 3.33M 1.96M
Income Tax - Deferred - Domestic
- - - -
-
Income Tax - Deferred - Foreign
7.00K 86.00K (3.71M) (2.18M)
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
(41.14M) (75.21M) (78.50M) (84.60M)
Minority Interest Expense
- - - -
-
Net Income
(41.14M) (75.21M) (78.50M) (84.60M)
Net Income Growth
-7.92% -82.82% -4.38% -7.76%
Net Margin Growth
-32.47% -46.51% -47.53% -50.95%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
(41.14M) (75.21M) (78.50M) (84.60M)
Preferred Dividends
- - - -
-
Net Income Available to Common
(41.14M) (75.21M) (78.50M) (84.60M)
EPS (Basic)
-1.7161 -3.0751 -3.0665 -3.0039
EPS (Basic) Growth
-4.96% -79.19% +0.28% +2.04%
Basic Shares Outstanding
23.97M 24.46M 25.60M 28.16M
EPS (Diluted)
-1.7161 -3.0751 -3.0665 -3.0039
EPS (Diluted) Growth
-4.96% -79.19% +0.28% +2.04%
Diluted Shares Outstanding
23.97M 24.46M 25.60M 28.16M
EBITDA
(21.03M) (35.49M) (60.14M) (42.41M)
EBITDA Growth
+13.27% -68.72% -69.47% +29.48%
EBITDA Margin
-16.60% -21.95% -36.42% -25.54%

Snapshot

Average Recommendation BUY Average Target Price 82.00
Number of Ratings 9 Current Quarters Estimate -0.469
FY Report Date 03 / 2026 Current Year's Estimate -1.05
Last Quarter’s Earnings -0.24 Median PE on CY Estimate N/A
Year Ago Earnings -1.863 Next Fiscal Year Estimate 0.078
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 7 7 9 9
Mean Estimate -0.47 -0.30 -1.05 0.08
High Estimates -0.35 -0.15 -0.30 1.10
Low Estimate -0.59 -0.37 -1.37 -0.65
Coefficient of Variance -21.05 -24.19 -31.91 649.65

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 8 8 8
OVERWEIGHT 0 0 0
HOLD 1 1 1
UNDERWEIGHT 0 0 0
SELL 0 0 0
MEAN Buy Buy Buy

Insider Actions for Establishment Labs Holdings Inc - ESTA

Date Name Shares Transaction Value
Jan 7, 2026 Edward J. Schutter Director 138,272 Grant, award or other acq pursuant to Rule 16b-3(d) Non-derivative transaction at $72.88 per share 10,077,263.36
Jan 7, 2026 Nicholas S. Lewin Director 1,076,875 Grant, award or other acq pursuant to Rule 16b-3(d) Non-derivative transaction at $72.88 per share 78,482,650.00
Jan 7, 2026 Leslie G. Gillin Director 15,747 Grant, award or other acq pursuant to Rule 16b-3(d) Non-derivative transaction at $72.88 per share 1,147,641.36
Jan 7, 2026 Bryan Slotkin Director 29,970 Grant, award or other acq pursuant to Rule 16b-3(d) Non-derivative transaction at $72.88 per share 2,184,213.60
Jan 7, 2026 Ann Custin Director 21,369 Grant, award or other acq pursuant to Rule 16b-3(d) Non-derivative transaction at $72.88 per share 1,557,372.72
Nov 11, 2025 JW Asset Management LLC 3,075,194 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $65 per share 199,887,610.00
Aug 12, 2025 Peter Caldini Chief Executive Officer; Director 35,245 Open market or private purchase of non-derivative security Non-derivative transaction at $35.2 per share 1,240,624.00
Apr 7, 2025 Rajbir S. Denhoy Chief Financial Officer 23,348 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Apr 7, 2025 Rajbir S. Denhoy Chief Financial Officer 19,716 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Apr 7, 2025 S. Ross Mansbach 15,238 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Apr 7, 2025 S. Ross Mansbach 13,998 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Apr 7, 2025 Peter Caldini Int Chief Executive Officer 30,333 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 21, 2025 Filippo Caldini Int Chief Executive Officer 8,308 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $34.82 per share 289,284.56

Establishment Labs Holdings Inc in the News